Palbociclib, Pfizer

Drug: Palbociclib
Company: Pfizer
Phase: Phase III
Class: Cyclin-dependent kinase (CDK) 4&6 inhibitor
2020 sales: $2.95 billion
Net present value: $7.9 billion

After going through the biggest R&D reorganization in industry history, Pfizer ($PFE) was left with a rather thin pipeline for a Big Pharma player. Palbociclib is one of a handful of standout programs at the company. But when it broadcast the news last May that it will go ahead and file for an approval for palbociclib, a closely-watched CDK 4/6 inhibitor, on Phase II data, the market essentially shrugged. Pfizer CEO Ian Read was being publicly chided at the time for pushing a megamerger with AstraZeneca ($AZN) long after Pfizer had provided ample evidence that megamergers typically flop. And the news couldn't overcome some miserable Q1 numbers that illustrated just how badly the company needs to do something effective. As it stands, some of the top analysts in the biz give palbociclib a solid shot at an accelerated approval. But even if it does come in around $3 billion--a rosy forecast--serious competition is coming up from behind.

For more:
Why did Pfizer's big fiesta for palbociclib fizzle?
Pfizer's flagship palbociclib stymies cancer progression but falls short on survival
All eyes on Pfizer as palbociclib prepares to take the stage

Palbociclib, Pfizer

Suggested Articles

Avidity Biosciences is on a roll—after inking an R&D deal with Eli Lilly and hiring a new CEO, the company is reeling in $100 million.

What the NASH field needs, says Genfit CEO Pascal Prigent, is something like the Hb1Ac test for diabetes.

Blocking a newly discovered molecule produced by B cells could slow their flow into the brain and offer a new way to treat MS, a Canadian team found.